Literature DB >> 14700448

Achieving remission and managing relapse in depression.

Michael E Thase1.   

Abstract

Although antidepressants are effective, no more than one third of the depressed patients who begin treatment achieve full remission within 8 weeks of therapy. Remission, defined as virtually complete relief of symptoms and return to full functioning in all areas of life, should be thought of as the optimal goal for the initial phase of treatment of depression. This goal is recommended because residual symptoms (i.e., response without remission) are associated with a myriad of risks, including a higher rate of relapse. When compared with monotherapy, selective serotonin reuptake inhibitor (i.e., the current first-line standard of care) strategies may improve remission rates. These strategies include using maximally tolerated (i.e., higher than usual) doses of medication, switching to an antidepressant thought to have more than one mechanism of action, combining dissimilar medications (to presumably treat a broader range of symptoms), and using a combination of psychotherapy and medication. Ensuring that patients are indeed adherent with treatment is also worthwhile before assuming that a treatment has failed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14700448

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  16 in total

1.  Vitamin D and depression: where is all the sunshine?

Authors:  Sue Penckofer; Joanne Kouba; Mary Byrn; Carol Estwing Ferrans
Journal:  Issues Ment Health Nurs       Date:  2010-06       Impact factor: 1.835

2.  Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a randomized controlled trial.

Authors:  Helen Lavretsky; Lily L Alstein; Richard E Olmstead; Linda M Ercoli; Marquertie Riparetti-Brown; Natalie St Cyr; Michael R Irwin
Journal:  Am J Geriatr Psychiatry       Date:  2011-10       Impact factor: 4.105

Review 3.  Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.

Authors:  J K Hicks; J J Swen; C F Thorn; K Sangkuhl; E D Kharasch; V L Ellingrod; T C Skaar; D J Müller; A Gaedigk; J C Stingl
Journal:  Clin Pharmacol Ther       Date:  2013-01-16       Impact factor: 6.875

4.  A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults With Major Depression and Subjective Memory Complaints.

Authors:  Helen Lavretsky; Kelsey T Laird; Beatrix Krause-Sorio; Brandon F Heimberg; Jillian Yeargin; Adrienne Grzenda; Pauline Wu; Kitikan Thana-Udom; Linda M Ercoli; Prabha Siddarth
Journal:  Am J Geriatr Psychiatry       Date:  2019-08-22       Impact factor: 4.105

5.  Predicting treatment outcome in depression: an introduction into current concepts and challenges.

Authors:  Nicolas Rost; Elisabeth B Binder; Tanja M Brückl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-19       Impact factor: 5.270

Review 6.  Tai Chi and Qigong for the treatment and prevention of mental disorders.

Authors:  Ryan Abbott; Helen Lavretsky
Journal:  Psychiatr Clin North Am       Date:  2013-03

7.  Preventing recurrent depression: long-term treatment for major depressive disorder.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 8.  Somatic symptoms in depression.

Authors:  Hans-Peter Kapfhammer
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 9.  Future prospects in depression research.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

10.  Factors Influencing Depression Endpoints Research (FINDER): baseline results of Italian patients with depression.

Authors:  Luigi Grassi; Andrea Rossi; Alessandra Barraco
Journal:  Ann Gen Psychiatry       Date:  2009-05-29       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.